IVA, Japan Society for the Promotion of Science, The Chemical Society of Japan, Sweden-Japan Foundation and The Japanese Embassy welcome you to a seminar on 3 March 2014
The pharmaceutical industry is still a highly profitable business.Nevertheless, the sector is facing a number of major challenges. One is the declining productivity of industrial R&D. Over the past decades the number of new medicines generated per R&D dollar spent has markedly decreased. New technologies, as well as new ways of organizing research, are needed to address this issue. This seminar focuses on the use of innovative chemistry to support drug discovery.
|■ Anders Ekblom, former CEO of AstraZeneca Sweden and Global Head of Science and Technology Integration|
|Professor Hiroaki Suga, The University of Tokyo
'Pseudo‐Natural Product Synthesis and Drug Applications'
|Professor Gunnar von Heijne, Stockholm University
'Using non-proteinogenic amino acids to study membrane protein biogenesis'
|Dr.Annika Jenmalm-Jensen, Chemical Biology Consortium Sweden
'Chemical Biology Consortium Sweden'
|Dr.Bjorn Odlander, Health Cap
'The Investor's Perspective'
|Hiroaki Suga, Gunnar von Heijne, Annika Jenmalm-Jensen, Bjorn Odlander and Anders Ekblom
'Panel Discussion: The potential of innovative chemistry to strengthen drug discovery and what Sweden and Japan can learn from each other'
|Date||Wednesday, March 3th, 17:00‐19:00, followed by dinner|
|Venue||IVA's Conference Centre, Grev Turegatan 16, Stockholm, Sweden.|
|Registration||Please register HERE no later than 24 February. The cost of dinner is SEK 400 (incl. SEK 80 VAT) and should be paid into "bankgiro 5108-2527." Please state 5082 as reference. Participation in the seminar is free of charge. IVA's corporate id number is 262000-1160.|